Mochida Pharmaceutical Company, Ltd.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Tokyo Japan (2013)

Organization Overview

First Clinical Trial
2013
NCT00231738
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Clinical Research Department | Mochida Pharmaceutical Company, Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 4)

Angina, Unstable (Phase 4)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Death (Phase 4)

Death, Sudden, Cardiac (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Fatty Liver (Phase 2)

Gout (Phase 3)

Hepatic Insufficiency (Phase 1)

Hypertriglyceridemia (Phase 3)

Hyperuricemia (Phase 3)

Infarction (Phase 4)

Liver Failure (Phase 1)

Myocardial Infarction (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 2)

Peripheral Arterial Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 9